J P Leonard
Overview
Explore the profile of J P Leonard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
2202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Czuczman M, Leonard J, Jung S, Johnson J, Hsi E, Byrd J, et al.
Ann Oncol
. 2018 Feb;
29(11):2271.
PMID: 29390097
No abstract available.
2.
MARTIN P, Jung S, Pitcher B, Bartlett N, Blum K, Shea T, et al.
Ann Oncol
. 2017 Sep;
28(11):2806-2812.
PMID: 28945884
Background: This multicenter, phase II trial tested the tolerability and efficacy of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma (FL). Patients And Methods: Patients with grade 1-3a...
3.
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al.
Ann Oncol
. 2017 Apr;
28(7):1436-1447.
PMID: 28379322
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased....
4.
Cheng S, Ma J, Guo A, Lu P, Leonard J, Coleman M, et al.
Leukemia
. 2013 Nov;
28(3):649-57.
PMID: 24270740
Bruton agammaglobulinemia tyrosine kinase (BTK), a cytoplasmic protein tyrosine kinase, is a component of the B-cell receptor signaling pathway. Ibrutinib, a BTK inhibitor, has demonstrated a significant clinical activity against...
5.
Czuczman M, Leonard J, Jung S, Johnson J, Hsi E, Byrd J, et al.
Ann Oncol
. 2012 Feb;
23(9):2356-2362.
PMID: 22357442
Background: This phase II CALGB trial evaluated the activity and safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular lymphoma (FL). Patients And Methods:...
6.
Lee S, Hershman D, MARTIN P, Leonard J, Cheung Y
Ann Oncol
. 2011 May;
23(2):537-41.
PMID: 21536663
Background: Toxicity data from cancer trials are summarized into a single outcome, dose-limiting toxicity (DLT), which does not account for multiple lower grade toxic effects nor differentiates between toxicity types...
7.
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors
Thompson C, Charlson M, Schenkein E, Wells M, Furman R, Elstrom R, et al.
Ann Oncol
. 2010 Apr;
21(11):2262-2266.
PMID: 20423914
Background: We aimed to assess anxiety and the psychological impact of routine surveillance scans in long-term survivors of adult aggressive lymphoma. Patients And Methods: In this cross-sectional observational study of...
8.
Leonard J, BROTT W
J Am Osteopath Assoc
. 2010 Mar;
46(12):629.
PMID: 20257407
No abstract available.
9.
Leonard J, Chung S, Nettleship I, Soong Y, Martello D, Chyu M
J Nanosci Nanotechnol
. 2009 Feb;
8(12):6361-6.
PMID: 19205207
Aqueous zinc oxide (ZnO) suspensions were prepared using a two-step preparation method in which an aggregated nanocrystalline ZnO powder was dispersed in water using a polyelectrolyte. The fluid showed anomalously...
10.
Ruan J, Hajjar K, Rafii S, Leonard J
Ann Oncol
. 2008 Dec;
20(3):413-24.
PMID: 19088170
Angiogenesis, the growth of new blood vessels, requires dynamic expansion, assembly and stabilization of vascular endothelial cells in response to proangiogenic stimuli. Antiangiogenic strategies have become an important therapeutic modality...